Quick summary
PEG-MGF is a PEGylated form of Mechano Growth Factor, an IGF-1 splice variant that activates muscle satellite cells. PEGylation extends half-life from minutes to 24-72 hours; preclinical studies show accelerated muscle repair, though no human trials exist.
Overview
PEG-MGF (PEGylated Mechano Growth Factor) is a synthetic, polyethylene glycol-modified form of MGF, which is itself a splice variant of IGF-1 (Insulin-like Growth Factor 1) released in response to mechanical stress on muscle tissue. PEGylation dramatically extends the half-life from minutes to 24–72 hours, enabling less frequent dosing while preserving the satellite cell-activating and myoblast-proliferating properties of native MGF.
Mechanism of action
MGF is generated by alternative splicing of the IGF-1 gene in mechanically stressed muscle. Its unique C-terminal E-domain peptide activates quiescent muscle satellite cells — the resident stem cells responsible for muscle repair and hypertrophy. PEG-MGF binds IGF-1 receptors and MGF-specific receptors on muscle cell membranes, triggering downstream Akt/mTOR and MAPK/ERK signaling that promotes myoblast proliferation, differentiation, and fusion into new myofibers. The PEG modification (polyethylene glycol conjugation) shields the peptide from proteolytic degradation and renal clearance, extending systemic availability from the native MGF half-life of approximately 5–7 minutes to an estimated 24–72 hours.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| muscle repair and satellite cell activation (research) | subcutaneous | 200–400 mcg | 2–3 times per week | Typical research cycle: 4–6 weeks. Inject post-workout or near target muscle. Do not exceed 8 weeks without a break. Research use only. |
| muscle repair (intramuscular, research) | intramuscular | 200–400 mcg | 2–3 times per week | IM injection into target muscle group studied for localized satellite cell activation. Research use only. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Preclinical studies demonstrate PEG-MGF's ability to activate satellite cells and accelerate muscle repair following injury in rodent models, with significant gains in fiber cross-sectional area and reduced necrosis markers. It has shown promise for muscle-wasting conditions in animal models. No human clinical trials have been completed as of 2026. Community use among bodybuilders and recovery athletes is reported, but human pharmacokinetic data remain limited. It is often compared to IGF-1 LR3 but with a distinct tissue-remodeling profile.[1][2][3][4][5]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with PEG-MGF for synergistic effects.
Legal status
Not FDA approved. Available from research peptide suppliers in the US as a laboratory compound. WADA-prohibited in competitive sport. Not scheduled as a controlled substance in most jurisdictions, but legal status varies.
Sourcing & access
Research compound
PEG-MGF is classified as a research compound. Regulatory status varies by jurisdiction. Always verify current legal status and source from vendors providing third-party certificates of analysis (COA).
Frequently asked questions
PEG-MGF (PEGylated Mechano Growth Factor) is a synthetic, polyethylene glycol-modified form of MGF, an IGF-1 splice variant released during mechanical muscle stress. It activates quiescent muscle satellite cells to promote muscle repair and hypertrophy.
PEG-MGF binds IGF-1 receptors and MGF-specific receptors on muscle cells, triggering Akt/mTOR and MAPK/ERK signaling to promote myoblast proliferation and differentiation. The PEG modification shields it from proteolytic degradation, extending its half-life from about 5-7 minutes to an estimated 24-72 hours.
Human safety data is limited. Reported side effects include injection site pain or swelling, hypoglycemia risk from IGF-1 pathway activity, water retention, and theoretical concern about accelerating existing neoplastic tissue growth. It is WADA-prohibited in competitive sport.
Both are IGF-1 axis peptides, but PEG-MGF specifically activates muscle satellite cells for tissue remodeling, while IGF-1 LR3 has broader systemic anabolic effects. PEG-MGF has a distinct tissue-remodeling profile focused on new myofiber formation.
Research references
- The E-domain region of mechano-growth factor inhibits cellular apoptosis and preserves cardiac function during myocardial infarctionPubMed
- Administration of a synthetic peptide derived from the E-domain region of mechano-growth factor delays decompensation following myocardial infarctionPubMed
- Localized delivery of mechano-growth factor E-domain peptide via polymeric microstructures improves cardiac function following myocardial infarctionPubMed
- Separation of fast from slow anabolism by site-specific PEGylation of insulin-like growth factor I (IGF-I)PubMed
- Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiationPubMed